Dr. Andrés Cervantes Ruipérez

Investigador Principal
Grupo de Investigación en cáncer colorrectal y nuevos desarrollos terapéuticos en tumores sólidos

Presentación

El Dr. Andrés Cervantes es catedrático de Medicina en la Universidad de Valencia y Jefe del Servicio de Oncología Médica en el Hospital Clínico Universitario de Valencia. Tras completar su formación especializada, trabajó en el laboratorio de farmacología celular del Free University Hospital en Amsterdam, donde obtuvo su Doctorado, con un trabajo sobre la resistencia a múltiples fármacos en tumores sólidos.

También es director del Área de Cáncer en el Instituto de Investigación Sanitaria – INCLIVA. Sus principales áreas de interés e investigación son el cáncer gastrointestinal, así como ensayos fase I y de desarrollo de nuevos fármacos y desarrollo de nuevas terapias experimentales. Es investigador clínico de cáncer rectal, un tema en el que ha desarrollado varias publicaciones sobre la calidad del trabajo multidisciplinar así como la evaluación de la calidad de la cirugía mesorrectal, cómo optimizar la elección idónea de la terapia inicial y, especialmente, cómo tratar el cáncer del tercio superior del recto.

Ha colaborado en la elaboración de guías clínicas internacionales y es coautor de estudios cooperativos internacionales que han modificado la práctica clínica. Su tema principal de trabajo actual es sobre la detección y análisis de la enfermedad mínima residual en cáncer de colon resecado con intención curativa mediante la detección de DNA circulante tumoral en plasma.

Es autor de más de 600 artículos y revisiones de trabajos publicados en diferentes revistas internacionales. Es también Editor Jefe de la revista Cancer Treatment Reviews y Editor Asociado de la sección de cancer gastrointestinal en Annals of Oncology. Es actualmente Presidente de ESMO (Sociedad Europea de Oncología Médica), para el periodo 2023-2024. Desde 2017 es director científico de INCLIVA.

Dr. Andrés Cervantes Ruipérez
Investigador
Principal
Dr. Andrés Cervantes Ruipérez

andres.cervantes@uv.es

Publicaciones
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review. Ciardiello D, Mauri G, Sartore-Bianchi A, Siena S, Zampino M, Fazio N, Cervantes A. Cancer Treatment Reviews. 2024 Jan 12:124:102683. doi: 10.1016/j.ctrv.2024.102683. PMID: 38237253

Anti-TIGIT antibody tiragolumab alone or with atezolizumab in patients with advanced solid tumors a Phase 1a/1b nonrandomized controlled trial. Kim T, Bedard P, Lorusso P, Gordon M, Bendell J, Oh D, Ahn M, Garralda E, D’Angelo S, Desai J, Hodi F, Wainberg Z, Delord J, Cassier P, Cervantes A, Gil-Martin M, Wu B, Patil N, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho B. JAMA Oncology. 2023 Sep 28:e233867. doi: 10.1001/jamaoncol.2023.3867. PMID: 37768658

Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a Delphi consensus study in Europe. Kroese T, van Laarhoven H, Schoppman S, Deseyne P, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen H, Nordsmark M, Pfeiffer P, Elme A, Adenis A, Piessen G, Bruns C, Lordick F, Gockel I, Moehler M, Gani C, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, Cellini F, D’Ugo D, Roviello F, Bencivenga M, de Manzoni G, van Berge Henegouwen M, Hulshof M, van Dieren J, Vollebergh M, van Sandick J, Jeene P, Muijs C, Slingerland M, Voncken F, Hartgrink H, Creemers G, van der Sangen M, Nieuwenhuijzen G, Berbee M, Verheij M, Wijnhoven B, Beerepoot L, Mohammad N, Mook S, Ruurda J, Kolodziejczyk P, Polkowski W, Wyrwicz L, Alsina M, Pera M, Kanonnikoff T, Cervantes A, Nilsson M, Monig S, Wagner A, Guckenberger M, Griffiths E, Smyth E, Hanna G, Markar S, Chaudry M, Hawkins M, Cheong E, van Hillegersberg R, van Rossum P. European Journal of Cancer. 2023 Feb 24;185:28-39. doi: 10.1016/j.ejca.2023.02.015. PMID: 36947929

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL; GO42144 Investigator and Study Group; Han SW. Nature Medicine. 2023 Dec 5. doi: 10.1038/s41591-023-02696-8. PMID: 38052910

Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: phase 2 study results. Ciardiello F, Bang Y, Cervantes A, Dvorkin M, Lopez C, Metges J, Ruiz A, Calvo M, Strickland A, Kannourakis G, Muro K, Kawakami H, Wei J, Borg C, Zhu Z, Gupta N, Pelham R, Shen L. Cancer Medicine. 2023 Jun;12(12):13145-13154. doi: 10.1002/cam4.5997. PMID: 37260158

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon D, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y. Lancet Oncology. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. PMID: 37541273

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer. Martinelli E, Arnold D, Cervantes A, Stintzing S, Van Cutsem E, Tabernero J, Taieb J, Wasan H, Ciardiello F. Cancer Treatment Reviews. 2023 Apr;115:102541. doi: 10.1016/j.ctrv.2023.102541. PMID: 36931147

FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer. Cervantes A, Prager GW. ESMO Open. 2023 Feb 20;8(2):100883. doi: 10.1016/j.esmoop.2023.100883. PMID: 36812740

How organoids can improve personalized treatment in patients with gastro-esophageal tumors. Cabeza-Segura M, Garcia-Micò B, La Noce M, Nicoletti GF, Conti V, Filippelli A, Fleitas T, Cervantes A, Castillo J, Papaccio F. Current Opinion in Pharmacology. 2023 Feb 23;69:102348. doi: 10.1016/j.coph.2023.102348. PMID: 36842387

In the Literature: january 2023. Martin-Arana J, Gambardella V, Tarazona N, Cejalvo JM, Cervantes A. ESMO Open. 2023 Jan 3;8(1):100763. doi: 10.1016/j.esmoop.2022.100763. PMID: 36603523

In the literature: July 2023. Gambardella V, Gimeno-Valiente F, Roselló S, Cervantes A. ESMO Open. 2023 Aug;8(4):101612. doi: 10.1016/j.esmoop.2023.101612. PMID: 37467659

In the Literature: March 2023. Gambardella V, Tarazona N, Roda D, Cervantes A. ESMO Open. 2023 Apr;8(2):101203. doi: 10.1016/j.esmoop.2023.101203. PMID: 37018871

In the literature: May 2023. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2023 May 15;8(3):101562. doi: 10.1016/j.esmoop.2023.101562. PMID: 37196398

In the literature: September 2023. Lamarca A, Moreno V, Gambardella V, Cervantes A. ESMO Open. 2023 Oct 16;8(6):102032. doi: 10.1016/j.esmoop.2023.102032. PMID: 37852035

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Journal of Clinical Oncology. 2023 Nov 20;41(33):5080-5089. doi: 10.1200/JCO.22.02773. PMID: 37967516

Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery – a five-year follow-up of the RAPIDO Trial. Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Putter H, Berglund A, Cervantes A, Crolla RMPH, Hendriks MP, Capdevila J, Edhemovic I, Marijnen CAM, van de Velde CJH, Glimelius B, van Etten B. Annals of Surgery. 2023 Oct 1;278(4):e766-e772. doi: 10.1097/SLA.0000000000005799. PMID: 36661037

Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. Linares J, Sallent-Aragay A, Badia-Ramentol J, Recort-Bascuas A, Mendez A, Manero-Ruperez N, Re DL, Rivas EI, Guiu M, Zwick M, Iglesias M, Martinez-Ciarpaglini C, Tarazona N, Varese M, Hernando-Momblona X, Canellas-Socias A, Orrillo M, Garrido M, Saoudi N, Elez E, Navarro P, Tabernero J, Gomis RR, Batlle E, Pisonero J, Cervantes A, Montagut C, Calon A. Nature Communications. 2023 Feb 10;14(1):746. doi: 10.1038/s41467-023-36334-1. PMID: 36765091

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E. Annals of Oncology. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. PMID: 36307056

Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III CanStem303C Study. Shah M, Yoshino T, Tebbutt N, Grothey A, Tabernero J, Xu R, Cervantes A, Oh S, Yamaguchi K, Fakih M, Falcone A, Wu C, Chiu V, Tomasek J, Bendell J, Fontaine M, Hitron M, Xu B, Taieb J, Van Cutsem E. Clinical Colorectal Cancer. 2022 Nov 11:S1533-0028(22)00125-6. doi: 10.1016/j.clcc.2022.11.002. PMID: 36503738

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, Meniawy T, Baron-Hay S, Briscoe K, McCarthy N, Fountzilas C, Cervantes A, Ge R, Wu J, Spira A. British Journal of Cancer. 2023 Sep;129(5):797-810. doi: 10.1038/s41416-023-02349-0. PMID: 37474720

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu R, Mulansari N, Govind Babu K, Lee M, Tan C, Cornelio G, Chong D, Chen L, Tanasanvimon S, Prasongsook N, Yeh K, Chua C, Sacdalan M, Sow Jenson W, Kim S, Chacko R, Syaiful R, Zhang S, Curigliano G, Mishima S, Nakamura Y, Ebi H, Sunakawa Y, Takahashi M, Baba E, Peters S, Ishioka C, Pentheroudakis G. ESMO Open. 2023 May 24;8(3):101558. doi: 10.1016/j.esmoop.2023.101558. PMID: 37236086

Pharmacokinetics (PK) of Tiragolumab in first-in-human study in patients with mixed solid tumors (GO30103). Garralda E, Oh D, Italiano A, Bedard P, Delord J, Calvo E, LoRusso P, Wainberg Z, Cervantes A, Rodriguez-Vida A, Shemesh C, Sane R, Mendus D, Ding H, Hendricks R, Meng R, Cho B, Kim T, Wu B. Journal of Clinical Pharmacology. 2023 Dec 17. doi: 10.1002/jcph.2397. PMID: 38105505

Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies. Carneiro B, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma W, Coveler A, Powell S, Bastos B, Davis E, Sahai V, Mikrut W, Longstreth J, Smith S, Weiskittel T, Li H, Borden B, Harvey R, Sahebjam S, Cervantes A, Koukol A, Mazar A, Steeghs N, Kurzrock R, Giles F, Munster P. Clinical Cancer Research. 2023 Nov 20. doi: 10.1158/1078-0432.CCR-23-1916. PMID: 37982822

Preoperative treatment of locally advanced rectal cancer. Sebag-Montefiore D, Cervantes A, Rodel C. New England Journal of Medicine. 2023 Oct 26;389(17):1631. doi: 10.1056/NEJMc2309857. PMID: 37888929

Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction. Papaccio F, Garcia-Mico B, Gimeno-Valiente F, Cabeza-Segura M, Gambardella V, Gutierrez-Bravo MF, Alfaro-Cervello C, Martinez-Ciarpaglini C, Rentero-Garrido P, Zuniga-Trejos S, Carbonell-Asins JA, Fleitas T, Rosello S, Huerta M, Sanchez Del Pino MM, Sabater L, Roda D, Tarazona N, Cervantes A, Castillo J. Journal of Experimental & Clinical Cancer Research. 2023 Jan 6;42(1):8. doi: 10.1186/s13046-022-02591-z. PMID: 36604765

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. Rudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R, Villaflor V, Spahn J, Li S, Cha E, Riely G, Gettinger S. ESMO Open. 2023 Mar 3;8(2):101160. doi: 10.1016/j.esmoop.2023.101160. PMID: 36871392

Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer. Gimeno-Valiente F, Martín-Arana J, Tébar-Martínez R, Gambardella V, Martínez-Ciarpaglini C, García-Micó B, Martínez-Castedo B, Palomar B, García-Bartolomé M, Seguí V, Huerta M, Moro-Valdezate D, Pla-Martí V, Pérez-Santiago L, Roselló S, Roda D, Cervantes A, Tarazona N. ESMO Open. 2023 Nov 9;8(6):102051. doi: 10.1016/j.esmoop.2023.102051. PMID: 37951129

Strategies for improving detection of circulating tumor DNA using next generation sequencing. Roberto T, Jorge M, Francisco G, Noelia T, Pilar R, Andres C. Cancer Treatment Reviews. 2023 Sep;119:102595. doi: 10.1016/j.ctrv.2023.102595. PMID: 37390697

Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: a multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Kroese TE, van Rossum PSN, Nilsson M, Lordick F, Smyth EC, Rosati R, Nafteux P, D’Ugo D, Chaudry MA, Polkowkski W, Roviello F, Gockel I, Kolodziejczyk P, Haustermans K, Guckenberger M, Nordsmark M, Hawkins MA, Cervantes A, Fleitas T, van Cutsem E, Moehler M, Wagner AD, van Laarhoven HWM, van Hillegersberg R. European Journal of Surgical Oncology. 2023 Jan;49(1):21-28. doi: 10.1016/j.ejso.2022.09.012. PMID: 36184420

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. Ducreux M, Abou-Alfa G, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, Eng C, Galle P, Gill S, Gruenberger T, Haustermans K, Lamarca A, Laurent-Puig P, Llovet J, Lordick F, Macarulla T, Mukherji D, Muro K, Obermannova R, O’Connor J, O’Reilly E, Osterlund P, Philip P, Prager G, Ruiz-Garcia E, Sangro B, Seufferlein T, Tabernero J, Verslype C, Wasan H, Van Cutsem E. ESMO Open. 2023 May 30;8(3):101567. doi: 10.1016/j.esmoop.2023.101567. PMID: 37263081

The percentage of mesorectal infiltration as a prognostic factor after curative surgery for pT3 rectal cancer. Sancho-Muriel J, Giner F, Cholewa H, Garcia-Granero A, Roselló S, Flor-Lorente B, Cervantes A, Garcia-Granero E, Frasson M. Colorectal Disease. 2023 Jun;25(6):1135-1143. doi: 10.1111/codi.16522. PMID: 36790134

The prognostic potential of CDX2 in colorectal cancer: harmonizing biology and clinical practice. Badia-Ramentol J, Gimeno-Valiente F, Duréndez E, Martínez-Ciarpaglini C, Linares J, Iglesias M, Cervantes A, Calon A, Tarazona N. Cancer Treatment Reviews. 2023 Dec:121:102643. doi: 10.1016/j.ctrv.2023.102643. PMID: 37871463

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial. Dijkstra E, Zwart W, Nilsson P, Putter H, Roodvoets A, Meershoek-Klein Kranenbarg E, Frodin J, Nygren P, Ostergaard L, Kersten C, Verbiene I, Cervantes A, Hendriks M, Capdevila J, Edhemovic I, van de Velde C, Marijnen C, van Etten B, Hospers G, Glimelius B. ESMO Open. 2023 Mar 3;8(2):101158. doi: 10.1016/j.esmoop.2023.101158. PMID: 36871393

Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline. Cervantes A, Martinelli E. Annals of Oncology. 2023 Nov 7:S0923-7534(23)04335-1. doi: 10.1016/j.annonc.2023.10.129. PMID: 37951473

Ximenez E, Ruiperez A. Selective neoadjuvant therapy in locally advanced rectal cancer: Who and why?. Cirugia Espanola. 2023 May;101(5):309-311. doi: 10.1016/j.cireng.2022.11.007. PMID: 36423876

Young oncologists’ perspective on the role and future of the clinician-scientist in oncology. Lim K, Westphalen C, Berghoff A, Cardone C, Connolly E, Guven D, Kfoury M, Kocakavuk E, Mando P, Mariamidze E, Matikas A, Moutafi M, Oing C, Pihlak R, Punie K, Sanchez-Bayona R, Sobczuk P, Starzer A, Tecic Vuger A, Zhu H, Cruz-Ordinario M, Altuna S, Canario R, Vuylsteke P, Banerjee S, de Azambuja E, Cervantes A, Lambertini M, Mateo J, Amaral T. Esmo Open. 2023 Aug 31;8(5):101625. doi: 10.1016/j.esmoop.2023.101625. PMID: 37659290

Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, Sharma S, Renner D, Hafez D, Roda D, Huerta M, Rosello S, Madsen AH, Love US, Andersen PV, Thorlacius-Ussing O, Iversen LH, Gotschalck KA, Sethi H, Aleshin A, Cervantes A, Andersen CL. Clinical Cancer Research. 2022 Feb 1;28(3):507-517. doi: 10.1158/1078-0432.CCR-21-2404. PMID: 34625408

Clinical management of metastatic colorectal cancer in the era of precision medicine. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. CA-A Cancer Journal for Clinicians. 2022 Jul;72(4):372-401. doi: 10.3322/caac.21728. PMID: 35472088

Colorectal cancer survival: prevalence of psychosocial distress and unmet supportive care needs. Andreu Y, Martinez P, Soto-Rubio A, Fernandez S, Bosch C, Cervantes A. Supportive Care in Cancer. 2022 Feb;30(2):1483-1491. doi: 10.1007/s00520-021-06513-1. PMID: 34529142

Corrigendum to «Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up»: [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2022 Jun;33(6):666. doi: 10.1016/j.annonc.2022.03.009. PMID: 35365377

ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski R, Curigliano G, Felip E, Ferreira A, Ganz P, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge A, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni G. Annals of Oncology. 2022 Nov;33(11):1119-1133. doi: 10.1016/j.annonc.2022.07.1941. PMID: 35963481

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. Italiano A, Cassier PA, Lin C, Alanko T, Peltola KJ, Gazzah A, Shiah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V. Cancer Immunology Immunotherapy. 2022 Feb;71(2):417-431. doi: 10.1007/s00262-021-02973-w. PMID: 34216247

First-in-human phase I Study of the OX40 agonist MOXR0916 in patients with advanced solid tumors. Kim T, Burris H, de Miguel Luken M, Pishvaian M, Bang Y, Gordon M, Awada A, Camidge D, Hodi F, McArthur G, Miller W, Cervantes A, Chow L, Lesokhin A, Rutten A, Sznol M, Rishipathak D, Chen S, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu L. Clinical Cancer Research. 2022 Aug 15;28(16):3452-3463. doi: 10.1158/1078-0432.CCR-21-4020. PMID: 35699599

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T’jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. Cancer Chemotherapy and Pharmacology. 2022 Apr;89(4):499-514. doi: 10.1007/s00280-022-04414-6. PMID: 35298698

Impact of the COVID-19 pandemic on a cancer fast-track programme. Martinez M, Moragon S, Ortega-Morillo B, Monton-Bueno J, Simon S, Rosello S, Insa A, Viala A, Navarro J, Sanmartin A, Fluixa C, Julve A, Soriano D, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner M, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Cancer Control. 2022 Jan-Dec;29:10732748221131000. doi: 10.1177/10732748221131000. PMID: 36355430

In the literature: April 2022. Ciardiello D, Roda D, Gambardella V, Cervantes A. ESMO Open. 2022 Apr 23;7(3):100479. doi: 10.1016/j.esmoop.2022.100479. PMID: 35472677

In the literature: December 2021. Montagut C, Gambardella V, Cabeza-Segura M, Fleitas T, Cervantes A. ESMO Open. 2022 Feb;7(1):100352. doi: 10.1016/j.esmoop.2021.100352. PMID: 34920292

In the literature: February 2022. Gambardella V, Cejalvo JM, Gonzalez Barrallo I, Gimeno Valiente F, Cervantes A. ESMO open. 2022 Feb 23;7(2):100411. doi: 10.1016/j.esmoop.2022.100411. PMID: 35219243

In the literature: July 2022. Gambardella V, Martinelli E, Tarazona N, Cervantes A. ESMO Open. 2022 Aug;7(4):100556. doi: 10.1016/j.esmoop.2022.100556. PMID: 35961192

In the literature: November 2022. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2022 Nov 17;7(6):100643. doi: 10.1016/j.esmoop.2022.100643. PMID: 36403559

Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcon-Molero L, Gonzalez-Vilanova A, Zuniga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Dura A, Richart P, Alonso N, Huerta M, Rosello S, Roda D, Tarazona N, Martinez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. British Journal of Cancer. 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. PMID: 36253523

Minimal residual disease in gastroesophageal adenocarcinoma: thesearch for the invisible. Tarazona N, Gimeno-Valiente F, Cervantes A. ESMO Open. 2022 Aug;7(4):100547. doi: 10.1016/j.esmoop.2022.100547. PMID: 35849878

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. PMID: 35914638

Paclitaxel induces epidermal molecular changes and produces subclinical alterations in the skin of gynecological cancer patients. Montero P, Perez-Leal M, Perez-Fidalgo JA, Sanz C, Estornut C, Roger I, Milara J, Cervantes A, Cortijo J. Cancers. 2022 Feb 23;14(5):1146. doi: 10.3390/cancers14051146. PMID: 35267454

Quality of life in cancer survivorship: Sociodemographic and disease-related moderators. Andreu Y, Martinez P, Soto-Rubio A, Perez-Marin M, Cervantes A, Arribas L. European Journal of Cancer Care. 2022 Nov;31(6):e13692. doi: 10.1111/ecc.13692. PMID: 36069249

RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines. Albanell-Fernandez M, Oltra S, Orts-Arroyo M, Ibarrola-Villava M, Carrasco F, Jimenez-Marti E, Cervantes A, Castro I, Martinez-Lillo J, Ribas G. Cancers. 2022 Dec 22;15(1):69. doi: 10.3390/cancers15010069. PMID: 36612065

SMG8/SMG9 heterodimer loss modulates SMG1 kinase to drive ATR inhibitor resistance. Llorca-Cardenosa MJ, Aronson LI, Krastev DB, Nieminuszczy J, Alexander J, Song F, Dylewska M, Broderick R, Brough R, Zimmermann A, Zenke FT, Gurel B, Riisnaes R, Ferreira A, Roumeliotis T, Choudhary J, Pettitt SJ, de Bono J, Cervantes A, Haider S, Niedzwiedz W, Lord CJ, Chong IY. Cancer Research. 2022 Nov 2;82(21):3962-3973. doi: 10.1158/0008-5472.CAN-21-4339. PMID: 36273494

SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, Gonzalez B, Arance A, Martin-Liberal J, Gavila J, Lopez-Gonzalez A, Miguel Cejalvo J, Izarzugaza Y, Amillano K, Garcia Corbacho J, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesia R, Cervantes A, Tabernero J. Future Oncology. 2022 Oct 6. doi: 10.2217/fon-2022-0660. PMID: 36200668

The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. Van Schooten T, Derks S, Jimenez-Marti E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O’Connor J, Esteso F, Farres J, Mas J, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T. BMC Cancer. 2022 Jun 13;22(1):646. doi: 10.1186/s12885-022-09689-9. PMID: 35692051

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. Castelo-Branco L, Awada A, Pentheroudakis G, Perez-Gracia J, Mateo J, Curigliano G, Banerjee S, Giuliani R, Lordick F, Cervantes A, Tabernero J, Peters S. ESMO Open. 2021 Jul 24;6(5):100237. doi: 10.1016/j.esmoop.2021.100237. PMID: 34411971

Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 May;32(5):590-599. doi: 10.1016/j.annonc.2021.02.004. Epub 2021 Feb 17. PMID: 33609722

Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervello C, Garces-Albir M, Cervantes A, Ibarrola-Villava M. Cancers. 2021 Feb 27;13(5):994. doi: 10.3390/cancers13050994. PMID: 33673558

Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. Pavlidis N, Peccatori F, Aapro M, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Journal of Cancer Education. 2021 Oct;36(5):1124-1128. doi: 10.1007/s13187-020-01744-y. PMID: 32303982

Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Gambardella V, Martinez-Ciarpaglini C, Fleitas T, Cervantes A. ESMO Open. 2021 Nov 6;6(6):100285. doi: 10.1016/j.esmoop.2021.100285. PMID: 34752996

Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer. Gimeno-Valiente F, Riffo-Campos A, Torres L, Tarazona N, Gambardella V, Cervantes A, Lopez-Rodas G, Franco L, Castillo J. Cancers. 2021 Mar 21;13(6):1433. doi: 10.3390/cancers13061433. PMID: 33801071

ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. Annals of Oncology. 2021 Jul;32(7):823-824. doi: 10.1016/j.annonc.2021.04.001. PMID: 34090547

ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. ESMO open. 2021 Jul;32(7):823-824. doi: 10.1016/j.annonc.2021.04.001. PMID: 34144776

ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. Pavlidis N, Peccatori F, Aapro M, Eniu A, Stahel R, Cervantes A, Cavalli F, Costa A. Journal of Cancer Education. 2021 Jun;36(3):556-560. doi: 10.1007/s13187-019-01664-6. PMID: 31845109

First-in-human phase I study of a next-generation, oral, transforming growth factor-beta receptor 1 inhibitor, LY3200882 in patients with advanced cancer. Yap TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Lohr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. Clinical Cancer Research. 2021 Dec 15;27(24):6666-6676. doi: 10.1158/1078-0432.CCR-21-1504. PMID: 34548321

First-line biological agents plus chemotherapy in older patients with metastatic colorectal cancer: a retrospective pooled analysis. Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales M, Mozo J, Munoz A, Duran G, Sastre J, Safont M, Ferreiro R, Rivera F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, Alonso-Orduna V, Vieitez J, Yubero A, Aranda E, Spanish Cooperative Grp Treatment. Drugs & Aging. 2021 Mar;38(3):219-231. doi: 10.1007/s40266-021-00834-w. PMID: 33615402

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Lo Cascio A, Gandini S, Lizier M, Braga D, Asnicar F, Segata N, Klaver C, Brescia P, Rossi E, Anselmo A, Guglietta S, Maroli A, Spaggiari P, Tarazona N, Cervantes A, Marsoni S, Lazzari L, Jodice M, Giovanna L, Chiara E, Marco PS, Di Fiore PP, Viale G, Spinelli A, Pozzi C, Penna G, Rescigno M. Cancer Cell. 2021 May 10;39(5):708-724.e11. doi: 10.1016/j.ccell.2021.03.004. PMID: 33798472

In the literature: April 2021. Martin-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo J M, Cervantes A. ESMO open. 2021 Apr 19;6(3):100116. doi: 10.1016/j.esmoop.2021.100116. PMID: 33887688

In the literature: August 2021. Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, Cervantes A. ESMO Open. 2021 Aug 16;6(5):100247. doi: 10.1016/j.esmoop.2021.100247. PMID: 34411970

In the literature: December 2020. Gambardella V, Ibarrola-Villaba M, Tarazona N, Cervantes A. ESMO Open. 2021 Jan 4;6(1):100009. doi: 10.1016/j.esmoop.2020.100009. PMID: 33399075

In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. ESMO Open. 2021 Feb 24;6(2):100061. doi: 10.1016/j.esmoop.2021.100061. PMID: 33639602

In the literature: June 2021. Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. ESMO open. 2021 Jun;6(3):100186. doi: 10.1016/j.esmoop.2021.100186. PMID: 34098228

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Martinez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, Martinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa S, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta M, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. British Journal of Cancer. 2021 Oct;125(9):1261-1269. doi: 10.1038/s41416-021-01502-x. PMID: 34493820

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti B, Ahn J, Faud I, Chee C, Yeh K, Lin P, Chua C, Hasbullah H, Lee M, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Annals of Oncology. 2021 Dec;32(12):1496-1510. doi: 10.1016/j.annonc.2021.08.1752. PMID: 34411693

Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders. Pellino G, Garcia-Granero E, Cervantes A. European Journal of Surgical Oncology. 2021 Oct;47(10):2697. doi: 10.1016/j.ejso.2021.06.031. PMID: 34217579

Radiomics and radiogenomics in head and neck squamous cell carcinoma: potential contribution to patient management and challenges. Bruixola G, Remacha E, Jimenez-Pastor A, Dualde D, Viala A, Monton J, Ibarrola-Villava M, Alberich-Bayarri A, Cervantes A. Cancer Treatment Reviews. 2021 Sep;99:102263. doi: 10.1016/j.ctrv.2021.102263. PMID: 34343892

Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 Sep;32(9):1190-1191. doi: 10.1016/j.annonc.2021.05.795. PMID: 34033882

Retrospective study of regorafenib versus TAS-102 efficacy and safety in chemorefractory Metastatic Colorectal Cancer (mCRC) patients: a multi-institution real life clinical data. Vitale P, Zanaletti N, Famiglietti V, De Falco V, Cervantes A, Rosellò S, Fenocchio E, Milanesio M, Lombardi P, Ciardiello D, Martini G, Martinelli E, Ciardiello F, Troiani T, Napolitano S. Clinical Colorectal Cancer. 2021 Sep;20(3):227-235. doi: 10.1016/j.clcc.2021.06.002. PMID: 34226142

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer R, Dijkstra E, van Etten B, Marijnen C, Putter H, Kranenbarg E, Roodvoets A, Nagtegaal I, Beets-Tan R, Blomqvist L, Fokstuen T, Ten Tije A, Capdevila J, Hendriks M, Edhemovic I, Cervantes A, Nilsson P, Glimelius B, van de Velde C, Hospers G, RAPIDO collaborative investigators. Lancet. Oncology. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. PMID: 33301740

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. Malhi V, Budha N, Sane R, Huang J, Liederer B, Meng R, Patel P, Deng Y, Cervantes A, Tabernero J, Musib L. Cancer Chemotherapy and Pharmacology. 2021 Dec;88(6):921-930. doi: 10.1007/s00280-021-04344-9. PMID: 34471960

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. Martinez MT, Monton-Bueno J, Simon S, Ortega B, Moragon S, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. ESMO open. 2021 May 11;6(3):100148. doi: 10.1016/j.esmoop.2021.100148. PMID: 33989988

The COVID-19 pandemic could be a setback for gender equality in oncology-and a key moment to push ahead with transformative policies. Cervantes A. ESMO Open. 2021 Jun;6(3):100169. doi: 10.1016/j.esmoop.2021.100169. PMID: 34144777

Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project. Pellino G, Alós R, Biondo S, Codina-Cazador A, Enríquez-Navascues J, Espín-Basany E, Roig-Vila J, Cervantes Ruiperez A, Carceller R, Spanish Rectal Cancer Project collaborators. EJSO. 2021 Feb;47(2):276-284. doi: 10.1016/j.ejso.2020.04.056. PMID: 32950316

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Vogel A, Martinelli E, ESMO Guidelines Commite. Annals of Oncology. 2021 Jun;32(6):801-805. doi: 10.1016/j.annonc.2021.02.014. PMID: 33716105

Proyectos
Referencia: 101057514 – Mypath
Título: Developing and implementing innovative Patient-Centred Care Pathways for cancer patients
Entidad Financiadora: European Commission
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2022 – 2027
Presupuesto: 388,125 (Total: 4,773,470.00)
Referencia: PI21/00689
Título: Caracterización y abordaje de la enfermedad mínima residual en cáncer de colon localizado: un paso hacia la medicina de precisión
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Noelia Tarazona Llavero, Andrés Cervantes Ruipérez
Duración: 2022 – 2024
Presupuesto: 232.320 €
Referencia: ICI20/00009
Título: Investigación Clínica Independiente
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2021 – 2024
Presupuesto: 1.039.970 €
Referencia: PT20/00100
Título: Plataforma de Investigación Clínica
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2021 – 2023
Presupuesto: 199.650 €
Referencia: 825832 – LEGACy
Título: CeLac and European consortium for a personalized medicine approach to Gastric Cancer
Entidad Financiadora: European Commission
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2019 – 2023
Presupuesto: €3.577.431,27 (INCLIVA: €638.315)
Referencia: PI18/01909
Título: Medicina personalizada en pacientes con cáncer colorrectal localizado: abordaje multiómico de la Enfermedad Mínima Residual en biopsia líquida y modelos de organoides
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez, Desamparados Roda
Duración: 2019 – 2021
Presupuesto: 141.570 €
Referencia: PT17/0017/0003
Título: Plataforma de Investigación y Ensayos Clínicos
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2018 – 2021
Presupuesto: 266.475 €
Referencia: CB16/12/00473
Título: CIBER Oncología (CIBERONC)
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2017 –
Presupuesto:
Referencia: AC15/00096
Título: Evolution of resistant clones to novel target-directed drugs in colorectal tumours. A genetic and apigenetic study of intratumoral herterogeneity dynamics
Entidad Financiadora: European Commission (Programación conjunta internacional ISCIII)
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2016 – 2020
Presupuesto: 29.645 €
Referencia: MoTriColor
Título: Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor)
Entidad Financiadora: European Commission
Investigador principal: Josep Tabernero
Duración: 2015 – 2020
Presupuesto: 271.424 €
+ Información
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu R, Mulansari N, Govind Babu K, Lee M, Tan C, Cornelio G, Chong D, Chen L, Tanasanvimon S, Prasongsook N, Yeh K, Chua C, Sacdalan M, Sow Jenson W, Kim S, Chacko R, Syaiful R, Zhang S, Curigliano G, Mishima S, Nakamura Y, Ebi H, Sunakawa Y, Takahashi M, Baba E, Peters S, Ishioka C, Pentheroudakis G. ESMO Open. 2023 May 24;8(3):101558. doi: 10.1016/j.esmoop.2023.101558. PMID: 37236086

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E. Annals of Oncology. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. PMID: 36307056

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. PMID: 35914638

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Vogel A, Martinelli E, ESMO Guidelines Commite. Annals of Oncology. 2021 Jun;32(6):801-805. doi: 10.1016/j.annonc.2021.02.014. PMID: 33716105

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti B, Ahn J, Faud I, Chee C, Yeh K, Lin P, Chua C, Hasbullah H, Lee M, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Annals of Oncology. 2021 Dec;32(12):1496-1510. doi: 10.1016/j.annonc.2021.08.1752. PMID: 34411693

New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: 10.1016/j.annonc.2020.07.012. PMID: 32710931

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G, Ikeda M, Lim H, Ho G, Choo S, Ren Z, Malhotra H, Ueno M, Ryoo B, Kiang T, Tai D, Vogel A, Cervantes Ruiperez A, Lu S, Yen C, Huang Y, Chen S, Hsu C, Shen Y, Tabernero J, Yen Y, Hsu C, Yoshino T, Douillard J. Annals of Oncology. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. PMID: 32067677

Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2019 Oct 1;30(10):1558-1571. doi: 10.1093/annonc/mdz233. PMID: 31378807

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018). Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Annals of Oncology. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510. PMID: 30715202

Título: Tecnologías de secuenciación masiva y PCR digital en la detección de ADN tumoral procedente de tejido y plasma en pacientes de colon localizado
Doctorando: Tébar Martínez, Roberto
Director: Rentero Garrido, Pilar; Cervantes Ruipérez, Andrés; Tarazona Llavero, Noelia
Fecha: 01/02/2023
Universidad: Universitat de València

Título: Establecimiento de organoides derivados de pacientes con carcinoma colorrectal como modelo para cribado de drogas con acción antitumoral
Doctorando: Gutiérrez Bravo, Mª Fernanda
Director: Castillo Aliaga, Josefa; Cervantes Ruipérez, Andrés
Fecha: 04/02/2022
Universidad: Universitat de València

Título: Multi-omic characterization of advanced colorectal cancer patients derived organoids in the context of Precision Medicine
Doctorando: Papaccio, Federica
Director: Cervantes Ruipérez, Andrés; Castillo Aliaga, Josefa
Fecha: 23/12/2021
Universidad: Università della Campania Luigi Vanvitelli

Título: A multi-omic liquid biopsy-based signature as a valuable tool to assess minimal residual disease in localised colorectal cancer
Doctorando: Tarazona Llavero, Noelia
Director: Cervantes Ruipérez, Andrés
Fecha: 23/07/2019
Universidad: Universitat de València

Título: Genetic determinants of atr inhibitor sensitivity and resistance in gastric cancer
Doctorando: Llorca Cardeñosa, Marta Jessica
Director: Cervantes Ruipérez, Andrés; Ribas Despuig, Gloria
Fecha: 22/07/2019
Universidad: Universitat de València